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LIST OF ABBREVIATIONS 
 
 
 
GORD/GERD  Gastroesophageal reflux disease 
LPR    Laryngopharyngeal reflux 
GPR    Gastropharyngeal reflux 
PCF    Pharyngocutaneous fistula 
PPI    Proton pump inhibitor 
TOF    Tracheoesophageal fistula 
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ABSTRACT 
 
 
DO PROTON PUMP INHIBITORS REDUCE THE INCIDENCE 
OF PHARYNGOCUTANEOUS FISTULAE FOLLOWING TOTAL 
LARYNGECTOMY? 
 
 
BACKGROUND: 
Pharyngocutaneous fistula is a common complication of total laryngectomy. 
We hypothesised that perioperative proton pump inhibitor (PPI) treatment 
could reduce the incidence of pharyngocutaneous fistulae. 
 
 
METHODS: 
This prospective placebo-controlled double-blind randomised controlled trial 
compared PPI treatment (14 days enteral omeprazole) with a placebo in 
patients undergoing primary total laryngectomy. The incidence of 
pharyngocutaneous fistula was recorded. 
 
RESULTS: 
Forty patients were randomised into PPI (N = 21) and placebo arms (N = 19). 
One of 21 patients receiving omeprazole developed a fistula in comparison to 
6 of 19 placebo group patients (p=0.04). No other statistically significant risk 
factors for pharyngocutaneous fistula were identified. The mean hospital stay 
of patients with and without a fistula was 32 and 7.5 days respectively.   
 
CONCLUSIONS: 
PPI prophylaxis was associated with a statistically significant reduction in 
pharyngocutaneous fistulae. As fistulae are associated with prolonged 
hospitalisation and morbidity, PPIs are recommended for patients undergoing 
total laryngectomy. 
 
 
 
 
 
 
 
 
 
Keywords: pharyngocutaneous, fistula, laryngectomy, reflux, proton pump 
inhibitors, omeprazole.
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PART A: PROTOCOL 
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BACKGROUND 
Pharyngocutaneous fistula (PCF) is a common complication following total 
laryngectomy and is a cause of significant patient morbidity. The reported 
incidence of PCF ranges from 3 to 65%; with a reported average of 17.4%;1 
the incidence at our centre has been previously evaluated and found to 
range between 15.4% and 20%.2  Spontaneous closure of PCF generally 
occurs. However surgical closure may be required, either by direct closure of 
the pharyngeal mucosa or by use of a tissue flap.  It has been demonstrated 
that development of PCF has been found to be associated with a significantly 
increased duration of hospital stay.  Fatal bronchopneumonia, mediastinitis 
and severe sepsis, in addition to death as a result of erosion of the carotid 
artery by a PCF have also been described. 
Numerous studies have examined the likely aetiology of PCF post-total 
laryngectomy; multiple risk factors have been thus far identified.3-8  Risk 
factors may be categorised into patient, disease and procedure-related 
factors, summarised below. 
Patient-related Disease / Management-related 
 
Co-morbid illness: 
 
Prior tracheostomy 
  CCF 
  Diabetes 
  Liver disease 
 
 
Concurrent neck dissection                          
 
Previous radiotherapy 
Low post-operative albumin 
 
Low post-operative haemoglobin /         
Peri-operative blood transfusion  
 
Post-operative vomiting 
 
Pharyngolaryngectomy 
 
Pharyngeal myotomy 
 Positive surgical margins 
 
Presence of lymph node 
metastases 
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Patients with HIV have been found to be at increased risk of developing 
squamous cell carcinoma of the larynx; the disease is also know to follow a 
more aggressive course with increased treatment-related morbidity.9 The 
influence of HIV status on the incidence of PCF has not been published. 
Gastro-oesophageal reflux disease (GORD) is also increasingly recognised 
as a potential aetiological factor for malignancy of the upper aero-digestive 
tract, including the larynx.  It has been estimated that the single greatest risk 
factor for squamous cell carcinoma (SCC) of the larynx is cigarette smoking. 
Alcohol consumption (in isolation) is also associated with an increased risk. 
Smoking and alcohol consumption are also major risk factors for GORD.10  A 
high incidence of GORD and GPR (gastropharyngeal reflux) has been 
detected in patients with SCC of the larynx in both the pre- and post-
laryngectomy population.11-13 
Not only is it suspected that reflux may play a role in the aetiology of 
squamous cell cancer of the larynx but also that it may contribute to 
complications in head and neck cancer patients after surgery or during 
radiotherapy.  Qadeer et al found that acid suppression therapy post-
laryngectomy may have protective effect on laryngeal cancer recurrence.14 
As a class, proton pump inhibitors (PPIs), such as omeprazole and 
lansoprazole, are the most potent suppressors of acid secretion. They act by 
irreversibly binding to and inhibiting the H+,K+-ATPase enzyme of the gastric 
parietal cell.  PPIs may be administered intravenously, orally and via a naso-
gastric feeding tube. 
Antacid medications are employed by some surgeons in the post-operative 
period following total laryngectomy with the aim of reducing the incidence of 
post-operative pharyngocutaneous fistulae. To date, medical literature 
describes the use of H2 antagonists (such as cimetidine and ranitidine) as 
antacids. Seikaly and Park reported a significant decrease in the incidence of 
PCF with a post-operative regimen of intravenous ranitidine and 
metocloperamide hydrochloride (a prokinetic);15 Twenty-three prospective 
cases were treated with the antacid regime (PCF incidence 0%), in 
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comparison to 17 retrospective controls that did not receive antactid 
treatment (PCF incidence 26%).  A significant reduction in PCF incidence 
was also described by Sarria Echegaray et al in 2000 following the addition 
of a prokinetic medication to their post-operative regime.16 
To the knowledge of the investigators, neither the use of PPIs, nor the use of 
an enteral antacid preparation, has been examined; an exciting potential 
application of the PPI as gasto-oesophageal reflux prophylaxis exists in the 
post-total laryngectomy setting.  
PURPOSE OF THE STUDY 
The primary aim of the study is to determine whether administration of a PPI 
in the immediate postoperative period reduces the incidence of 
pharyngocutaneous fistula in patients who have undergone total 
laryngectomy.  Our hypothesis is that PPIs reduce the incidence of PCF 
post-laryngectomy. 
METHODOLOGY 
STUDY DESIGN 
A prospective randomised controlled trial; it will be a placebo-controlled, 
double blind study (materials permitting).  
A PPI, 20mg omeprazole, will be administered once daily for 14 consecutive 
days. The first dose will be given the day before total laryngectomy.  Initial 
post-operative administration will be via the naso-gastric (NG) feeding tube 
and then per os when the patient is feeding orally.  The MUPS preparation of 
omeprazole is suitable for use via an NG tube. An oral preparation of 
omeprazole may otherwise be used when the patient is not dependent on 
NG feeding. Both preparations are stocked by the Groote Schuur Hospital 
pharmacy. It is the investigators’ wish that widely available and therefore 
clinically applicable preparations be used.   
It is appropriate that existing prescribing guidelines, of both the 
manufacturers of the medication and of local pharmacology authorities 
(including the South African Medicines Formulary17) are followed.  
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Recommended dosage is 20mg once daily for treatment of both gastric and 
duodenal ulcers, reflux oesophagitis, NSAID-associated gastroduodenal 
lesions, symptomatic gastro-oesophageal reflux disease and functional 
dyspepsia, in addition to the prophylaxis of NSAID-associated 
gastroduodenal lesions.  
Within communications with possible manufacturers of the placebo drug, it 
has been and will continue to be stressed by the investigators that the 
placebo and associated paraphernalia must be identical to that of the active 
drug. The tablet or capsule must be of identical size, shape, colour, and 
weight. A placebo for the MUPS preparation which is to be dispersed in 
water must also have similar dispersing properties and appearance when 
dispersed. Furthermore the packaging and labelling of the placebo must also 
be identical, when viewed by the patient, nursing and medical staff. When the 
placebos are received from the manufacturer, it is intended that this will be 
verified by pharmacy staff.   
Following Health Sciences Faculty Human Research Ethics Committee (HSF 
HREC) approval, the study will be formally discussed with the Manager of the 
Inpatient Pharmacy of Groote Schuur Hospital, Mr. V. Naicker.  Pharmacy 
expertise will be sought and appreciated; jointly agreed procedures related to 
the study will be established and documented in writing.  It is intended that a 
specific, named pharmacist(s), holding Good Clinical Practice certification, be 
allocated to the study. This pharmacist(s) would be responsible for allocation 
of the grouping nomenclature, supervision of storing and dispensing of 
materials, in addition to acting as a liaison between pharmacy and the 
investigators.  All materials related to the study (including both the active 
drug and placebo) will be stored in a separate, clearly labelled area within the 
inpatient pharmacy prior to dispensing. It is intended that both the active drug 
and placebos be dispensed by the F8 ward nursing staff in the standard 
manner along with any other medications the patients may be receiving.  
Specific information sessions regarding the study, both prior to the start of 
the study and at regular intervals within the study, will be conducted with the 
ward staff that will be sending the patient medication charts to the Inpatient 
Pharmacy and dispensing medications. 
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In order to conceal the identity of the drug and the placebo, patients will be 
randomised into one of two treatment groups.  The assignment of the active 
drug and the placebo will be made by and known only to allocated pharmacy 
staff.  Accordingly, nursing staff of the ENT ward (F8), medical staff within the 
ENT department including the investigators of the study will be unaware of 
the grouping. Only upon formal closure of the trial will the true identity of the 
two groups be revealed to the investigators. 
This grouping will be reflected by a special sticker label placed on the 
patient’s hospital folder and also on the patient’s inpatient medication chart. 
In addition to stating the grouping of the patient, this sticker will detail the 
patient hospital number, the name of the trial, the names and contact details 
for the investigators, and names and contact details of allocated 
pharmacist(s). The sticker labels will be of a bright colour in order to facilitate 
recognition.   
Accordingly, when a request for dispensing of medication is made to 
inpatient pharmacy by means of the medication chart, the 14-day course may 
be dispensed. This course will be started on the day immediately preceding 
the day of the total laryngectomy surgery and be continued for 14 
consecutive days. The treatment will therefore will be taken initially as an 
inpatient and either completed within the inpatient stay (if the inpatient stay is 
greater than 13 post-operative days), or completed at home (if the patient is 
discharged before the 13th post-operative day). 
Patients will be randomised shortly before total laryngectomy.  The total 
laryngectomy surgery and the postoperative care will remain unchanged 
other than the addition of the PPI.  The surgical method of closure of pharynx 
will be standardised: 2 layer closure with a vicryl suture, with the least wound 
tension (either a horizontal or T-shaped suture line), performed either by a 
consultant or by a trainee under consultant supervision. 
The principal outcome of the study is the development (or lack of 
development) of a pharyngocutaneous fistula (PCF); this objective outcome 
usually occurs within 10 days of surgery. Existing departmental procedure 
will continue to be followed; wounds are reviewed by an ENT Registrar 
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and/or Consultant on a daily basis whilst the patient is an inpatient and 
subsequently at each outpatient encounter thereafter within the LE32 Radio-
Oncology clinic framework. 
A possible PCF will be detected clinically, as evidenced by wound 
breakdown, erythema, and/or leakage of serous, sanguinous or purulent fluid 
from a wound or the surrounding skin. 
Upon clinical suspicion of a PCF, every patient will undergo a radio-opaque 
contrast swallow at Groote Schuur Hospital.  This is consistent with existing 
departmental practice.  Radiological confirmation of the presence of a PCF in 
these cases will serve as an objective outcome measure.  
All patients will be followed within the existing follow-up framework of the 
LE32 Head and Neck cancer clinic.  
 
CHARACTERISTICS OF THE STUDY POPULATION 
All patients at Groote Schuur hospital undergoing total laryngectomy for 
squamous cell carcinoma of the larynx are potential participants.  Due to the 
nature of the study population, it is not expected that vulnerable patients will 
be among the patients enrolled (e.g. minors, terminally ill). 
We are planning a study of two independent groups; one group will be 
treated with a PPI (case group) and the second group will not receive the 
treatment (control group) with 1 treated per untreated case.  It is intended 
that the control group receive a placebo and that patients, nursing staff and 
clinicians are blinded to the patient’s group.  
Historical data from the department indicates that the ‘failure rate’ (rate of 
PCF) among controls is 0.2.2  If the true ‘failure rate’ for case subjects is 0.0, 
we will need to study 44 experimental subjects and 44 control subjects to be 
able to reject the null hypothesis that the ‘failure rates’ for case and control 
subjects are equal with probability (power) 0.8.   If the true ‘failure rate’ for 
case subjects is 0.01, 50 case and 50 control subjects will be needed. The 
Type I error probability associated with this test of this null hypothesis is 0.05 
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Using an alternative scenario, predicting a decrease in incidence from 0.2 
(20%) to 0.05 (5%), 88 patients would be required in each arm.  
It is therefore projected that our intended initial sample size will be 50 
patients in each arm of the study. It is recognised that this reflects a marked 
reduction in the incidence of PCF. Existing literature related to this study has 
however described a significant decrease in the incidence of PCF using a 
post-operative anti-acid regime; Seikaly and Park reported a decrease in 
incidence from 26% (controls; no antacids given) to 0% (cases; intravenous 
ranitidine and metocloperamide given).18  Furthermore, in terms efficacy of 
acid suppression, omeprazole has demonstrated therapeutic results superior 
to any other previous medical treatment.19 
 
RECRUITMENT AND ENROLMENT 
Patients will be enrolled prior to total laryngectomy surgery either in an 
outpatient clinic or ENT ward setting, after consent for surgery has been 
obtained. Patients will be enrolled by an ENT registrar or consultant. The 
study will not be advertised. 
According to the South African Medicines Formulary (8th edition), omeprazole 
is contraindicated in patients with cancer of the stomach and use is 
cautioned in patients with porphyria and severe liver disease.  It is not 
anticipated that patients with the aforementioned problems will be within the 
study population; however those conditions would also be considered as 
exclusion criteria. Patients with a known allergy to omeprazole will be 
excluded from the study along with those patients who do not consent to 
study inclusion 
 
RESEARCH PROCEDURES AND DATA COLLECTION METHODS 
Data will be recorded in relation to patient history, the characteristics of their 
disease and the operative management (detailed in Appendix I); this will be 
done by either the primary investigators or a registrar within the ENT 
department.  Care will be taken to ensure all potential confounding factors 
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will be recorded so that these may be taken into account during data 
analysis. 
Method of randomisation: Computer generated, on the basis of random 
permutation blocks within strata with multiple stratification variables, so that 
known risk factors for PCF may be taken into consideration during 
randomisation. 
Post-operatively, the standard existing management will be followed for post-
operative care.  This includes an antibiotic regime of a single dose of 
intravenous Kefzol given intraoperatively followed by 24 hours of intravenous 
antibiotics (Ampicillin 1g tds and Metronidazole 500mg tds). Post-operative 
feeding will be determined by the existing departmental Early Feeding 
Protocol (Appendix II). 
 
DATA SAFETY AND MONITORING 
The primary investigator will act as study co-ordinator and will be responsible 
for the safety of the collected data.  It is anticipated that interim analyses will 
be made (e.g. at 4-month intervals). Should a highly significant outcome be 
obtained earlier than projected, early closure of the study may be considered 
in order for change of practice and dissemination of findings.  
 
DATA ANALYSIS 
Statistical data analysis will be performed. We anticipate that a continuity-
corrected chi-squared statistic or Fisher’s exact test will be used to evaluate 
our hypothesis.   
RESULTS / OUTCOME MEASURES 
The incidence of pharyngocutaneous fistula will be compared between the 
two groups of patients. Patient demographics and other factors known to 
affect fistula rate will be recorded, and will be included in randomisation, 
where possible. Duration of post-operative hospital stay (until patient is fit for 
discharge from a surgical perspective) will also be recorded.  
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PROJECTED COSTS 
The cost of the omeprazole and placebos are the only projected costs.  
Current Groote Schuur pharmacy costing (state tender) for a 20mg MUPS 
preparation (AstraZeneca; MCC registration number 34/11.4.3/0223) 
estimates the cost per patient to be R273.75 for a 14 day course; a 20mg 
non-MUPS preparation (Dr.Reddy; MCC registration number 34/11.4.3/0300) 
would cost R7.35 for a 14 day course. The cost of medication may be offset 
by reduced costs in terms of both hospital stay and operating theatre use if 
the PPI is proven to reduce the incidence of PCF. 	  
Following ethics committee approval, an application to the South African 
Society of Otorhinolaryngology Head and Neck Surgery will be made for a 
research grant in order to cover these costs. It is anticipated that the MUPS 
preparation and equivalent placebos will need to be purchased for the study; 
Dr. Reddy pharmaceuticals has given an initial indication that they will donate 
the non-MUPS preparation and equivalent placebos. 
 
RISKS TO PATIENT 
The only alteration to patient care and therefore source of possible risk will 
be the addition of the PPI medication, received by half of the study 
population. PPIs have been extensively clinically tested and are widely used. 
Much of the side effects and concerns regarding omeprazole relate to 
administration in severely ill patients and to long term administration; the 
setting of this study encompasses neither of these special situations. 
Due to the nature of the total laryngectomy surgery and the associated 
necessary post-operative care, it is reasonable to estimate that patients 
within the study will be inpatients for a minimum of the first 5 days of the 14 
day-treatment course.  Patients receiving the active drug will therefore be 
monitored closely; possible side-effects are likely to be promptly identified 
and managed appropriately.                                                     
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POTENTIAL BENEFITS  
Patients in the PPI arm of the study may benefit, should PPIs be shown to be 
effective. A decreased incidence of PCF may be associated with less 
morbidity and mortality post-total laryngectomy, in addition to reduced 
hospital stay.  The study will also advance the local scientific knowledge and 
refine patient care.  It is hoped that publication of the research will also 
benefit national and international centres, facilitating an evidence-based 
approach to post-operative care of the laryngectomee. 
 
ALTERNATIVES TO PARTICIPATION 
Should a patient choose not to participate in the study, the patient will be 
cared for without prejudice or deviation from established departmental care.  
Surgery for cancer of the larynx is performed in several public hospital 
settings within South Africa in addition to the private sector. 
 
INFORMED CONSENT PROCESS 
Consent will be obtained in writing prior to total laryngectomy, either by the 
Primary Investigator or a specifically trained and instructed member of the 
ENT department (see Appendix I). The patient will be deemed to be 
competent to consent to inclusion in the study if he/she has been deemed 
competent to consent for total laryngectomy.  If the patient is not able to 
understand the language of the consent form, a translator who is unaffiliated 
to the study will be employed, and counter-signature given.  The study 
population will not include minors; a consent form suitable for adults has 
been prepared. 
It is existing departmental policy that all patients with cancer of the larynx due 
to undergo total laryngectomy surgery are offered HIV testing and 
appropriately counselled; this practice will not be amended. 
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PRIVACY AND CONFIDENTIALITY 
The primary investigator will act as study co-ordinator and will be responsible 
for the safety of the collected data. Data collected and recorded on data 
sheets will be computerised.  All materials will be kept in a locked room 
within the ENT ward.  Hospital number will be recorded as a patient identifier 
within the raw data in order to permit verification of information at later stages 
during analysis, if needed.  Patient-specific information will neither be 
required nor included during data analysis. 
 
REIMBURSEMENT FOR PARTICIPATION 
It is not expected that participants will incur any extra personal costs in terms 
of transport, time or healthcare costs. Patients will not be given an incentive, 
monetary or of any other kind, in return for study participation. 
 
EMERGENCY CARE AND INSURANCE FOR RESEARCH-RELATED 
INJURIES 
A need for emergency care and/or insurance is not anticipated. 
 
WHAT HAPPENS AT THE END OF THE STUDY? 
Should the hypothesis be statistically proven, and the medication shown to 
be efficacious and practically applicable in this setting, it is hoped and 
anticipated that a post-laryngectomy PPI be given to all patients in future. 
The investigators plan to submit findings of the study to an international 
scientific journal for publication. 
 
No proprietary interests to declare.   
No investigator will receive incentives for recruiting participants to the 
study. 	  
Word count: 3147  
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PART	  B:	  STRUCTURED	  LITERATURE	  REVIEW	  
	  
DO	  PROTON	  PUMP	  INHIBITORS	  REDUCE	  THE	  INCIDENCE	  OF	  
PHARYNGOCUTANEOUS	  FISTULAE	  FOLLOWING	  TOTAL	  
LARYNGECTOMY?	  
Introduction 
Total laryngectomy is the mainstay of treatment for advanced laryngeal 
cancer and has been performed for over 150 years since Billroth’s first 
description in the 1870s. This surgical removal of the entire larynx results in 
an anterior hypopharyngeal defect that is typically closed by suturing. The 
resultant suture line is of considerable length; in the range of 8-10cm. 
Meticulous approximation of this thin and delicate tissue is required to 
achieve closure of the defect and increase the likelihood of healing. Several 
centres have employed an alternative method of closure using a mechanical 
linear stapling device since its initial description in 1990;1 this is not used in 
our setting, where approximately 30 such surgeries are performed each year. 
In addition to careful surgical technique, current local perioperative practice 
includes 24 hours of intravenous antibiotics and use of an ‘early feeding’ 
protocol (Appendix III). Antacid treatments are not currently routinely given. 
Pharyngocutaneous fistula (PCF) is a common complication following total 
laryngectomy surgery and is a cause of significant patient morbidity. This 
salivary leak that communicates between the pharynx and the skin is 
associated with wound breakdown and typically occurs at the level of the 
surgical incision or less commonly in the region of the tracheal stoma.2 The 
reported incidence of PCF ranges from 3% to 65% with a reported average 
of 17.4%;3 the incidence at our centre has been previously evaluated and 
found to range between 15.4% and 20%.4 Spontaneous closure of a PCF 
generally occurs; however surgical closure may be required, either by direct 
closure of the pharyngeal mucosa or by use of a tissue flap. Development of 
a PCF delays oral feeding and is associated with a significantly increased 
duration of hospital stay. At our institution the median inpatient stay was 
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found to be 10.5 days for patients without PCF compared to 26 days for PCF 
cases.4 This significant increase in hospital stay is mirrored in similar 
literature. Fatal bronchopneumonia, mediastinitis and severe sepsis, in 
addition to death as a result of erosion of the carotid artery by a PCF have 
also been described.5–7 It is the principal short-term post-surgical 
complication to be avoided; all potential risk factors must therefore be 
minimised. 
 
Objectives and Search Strategy 
The objective of the literature review is firstly to review the existing evidence 
relating to the aetiology of PCF post-total laryngectomy and more specifically 
the role of gastroesophageal reflux in the laryngectomy patient. Existing 
levels of evidence and research methods employed will also be examined. 
Deficiencies in current published knowledge and scope for further research 
will be identified. 
A systematic search for relevant literature was conducted using Medline® 
and PubMed® systems. The following key words were used: reflux, 
laryngectomy, pharyngocutaneous fistula, salivary leak, larynx, cancer, 
prophylaxis, proton pump inhibitor. No relevant review was found in the 
Cochrane database. 
 
Aetiology of Pharyngocutaneous Fistula 
Numerous studies have examined the likely aetiology of PCF post-total 
laryngectomy. The meta-analysis of Paydarfar and colleagues3 published in 
2000 identified 65 studies relating to risk factors contributing to PCF 
formation, whilst the published literature extends over a period of 40 years.8,9 
Multiple risk factors have been thus far identified.10–14.Risk factors may be 
categorised into patient, disease and management-related factors, 
summarised below (Table 1). Preoperative radiotherapy is currently thought 
to be the most significant factor thus far identified.15,16 
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Patient-related Disease / Management-related 
Co-morbid illness:  congestive cardiac 
failure, diabetes, liver disease 
Prior tracheostomy 
Low postoperative haemoglobin /         
Peri-operative blood transfusion 
Concurrent neck dissection /     
Extension of surgery to the pharynx              
Postoperative vomiting Previous radiotherapy 
Low postoperative albumin Pharyngeal myotomy 
 
Positive surgical margins /                 
Presence of lymph node metastases 
 Method of pharyngeal closure  
 Use of peri-operative antibiotics 
Table 1: Proposed risk factors for development of pharyngocutanous fistula 
following total laryngectomy 
 
Retrospective cohort studies form the majority of the basis of this evidence. 
One of the largest cohorts was evaluated by White et al, evaluating a total of 
259 laryngectomy patients (Oxford Centre for Evidence Based Medicine 
Level of evidence 2B17).15 This was, however, a heterogeneous group of 113 
primary laryngectomies with the remainder comprised of ‘salvage 
laryngectomies’ (performed after failure of other primary treatment such as 
partial surgery, radiotherapy and chemoradiotherapy) and extended 
laryngectomies combined with pharyngectomy or glossectomy and with use 
of a variety of free flaps. Two particular variables were associated with an 
increased risk of PCF; prior radiotherapy (P=0.03) and hypothyroidism 
(P<0.0002). Study method relating to postoperative feeding and antibiotic 
protocol was not described.  
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Author Total no.  
(fistula rate) 
Factors described 
Aprigliano18, 1990 625 (9.1%) RT, NG tube use,  
Bresson et al19, 1974 148 (65.5%) RT, stage 
Cavalot et al16, 2000 293 (10.9%) RT, Hb, systemic disease 
Chee & Siow20, 1999 69 (15.9%) RT, positive margins 
Cummings et al21, 1977 155 (16.1%) RT 
Fradis et al22, 1995 56 (12.5%) RT, ND, stage, RT + ND 
Gall et al23, 1977 233 (4.3%) RT, site 
Hier et al24, 1993 126 (19.0%) RT, blood transfusion, stage 
Horgan & Dedo25, 1979 135 (14.8%) RT, antibiotics, ND, PT, systemic disease 
Ikiz et al26, 2000 92 (8.7%) RT, Blood transfusion, stage, PT 
Johansen et al27, 1988 106 (32.1%) RT, antibiotics (metronidazole), site 
Joseph & Shumrick28, 1973 23 (34.8%) RT, RT + ND 
Kent et al29, 1985 66 (7.6%) RT, ND, systemic disease, site, stage 
Krouse & Metson30, 1992 109 (4.6%) RT, systemic disease 
Lavelle & Maw8, 1972 170 (37.6%) RT + MD, Hb, PT, site, stage 
McCombe & Jones31, 1993 357 (23.5%) RT, ND, systemic disease, stage 
Moses et al32, 1993 132 (21.%) RT, postoperative feeding 
Natvig et al33, 1993 180 (11.7%) RT, postoperative feeding, ND 
Papazoglou et al34, 1994 31 (9.0%) RT, ND, systemic disease, site, stage 
Robbins et al35, 1972 23 (8.7%) RT, ND, site, stage 
Sarkar et al36, 1990 110 (27.3%) RT, ND 
Sheman & Spiro37, 1986 60 (11.7%) RT, ND 
Soylu et al38, 1998 295 (12.5%) Suture material, RT, ND, site, stage 
Stell & Cooney39, 1974 111 (15.3%) RT 
Thawley40, 1981 155 (2.6%) RT, site 
Virtaniemi et al12, 2001 133 (15.0%) RT, Type of RT, ND, site, stage 
Wei et al41, 1980 121 (22.3%) RT, Hb, ND 
Table 2: Relevant literature: fistula rates and potential aetiological factors 
described. 
(RT, prior radiotherapy; ND, concurrent neck dissection; Hb, Low 
postoperative haemoglobin; PT, prior tracheostomy). Bold = interpreted as 
statistically significant. 
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Table 2 summarises much of the available literature regarding the incidence 
of PCF and influencing factors, including many of the studies reviewed by 
both Paydarfar and Cavalot and colleagues in their meta-analyses.3,16 Only 
studies relating specifically to total laryngectomy surgery were included. 
Apparent disparity between studies is evident in addition to variation in both 
fistula incidence and factors evaluated. 
What Is The Role Of Reflux? 
Gastroesophageal reflux disease is defined as the presence of reflux-related 
symptoms or oesophageal mucosal damage caused by the reflux of gastric 
contents. A diagnosis of GORD can often be made by analysis of the typical 
symptoms of heartburn and regurgitation.42,43 The incidence of GORD in the 
general population has been estimated to be in the range of 7-12%.44 
Multiple additional head and neck symptoms can be attributed to reflux, 
including globus sensation, hoarseness, halitosis, chronic cough, 
laryngospasm and throat discomfort.45,46 These atypical symptoms may 
occur in the absence of typical reflux sensations. ‘Silent’ GORD describes 
reflux without either typical or atypical reflux symptoms reported. 
The question of the prevalence of silent reflux in the normal population has 
been examined and evaluated principally by 24-hour pH monitoring and/or 
endoscopy. Abnormal acid exposure was detected in up to 30% of healthy 
patients whilst a range of 10-15% of endoscopies demonstrated reflux-
related macroscopic or microscopic pathology.47  
The extent of gastroesophageal reflux has been further examined and the 
term laryngopharyngeal reflux (LPR) introduced. Also known as 
gastropharyngeal reflux (GPR) or extraoesophageal reflux, this defines 
retrograde movement of gastric contents to the level of the pharynx and 
larynx. The effect of this gastric refluxate upon the upper aerodigestive tract 
mucosal lining was clarified by several early experimental studies. Severe 
mucosal erosion, ulceration and submucosal haemorrhages were recorded 
as a result of exposure to pepsin alone or to pepsin and hydrochloric acid in 
rabbit and cat models.48,49 Pepsin, a proteolytic digestive enzyme, was found 
to be the primary injurious component of the refluxate with greatest activity at 
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acidic pH levels. Experimental studies have also shown that intermittent 
reflux of only 3 episodes per week is sufficient to produce laryngeal damage 
when mucosal injury is present.50  
GORD has been suspected to be a potential aetiological factor for both 
inflammatory disease and malignancy of the upper aero-digestive tract, 
including the larynx.  Whilst it has been estimated that the single greatest risk 
factor for squamous cell carcinoma (SCC) of the larynx is cigarette smoking, 
alcohol consumption is also associated with an increased risk and 
potentiates the risk when associated with smoking. Notably, smoking and 
alcohol consumption are also major risk factors for gastroesophageal reflux 
disease (GORD).51 The possible mechanisms of GORD carcinogenesis 
considered include chronic inflammation accompanied by the action of free 
radicals. Chronic inflammation results in a regular alternation of tissue 
damage and repair phases, known to have mutagenic potential. Free radicals 
produced by local neutrophils may cause cellular damage and necrosis.52  
A high incidence of GORD and GPR has been detected in patients with 
squamous cell carcinoma of the larynx in both pre- and post-laryngectomy 
populations. Ambulant 24-hour pH monitoring has been demonstrated to be 
the most reliable and accurate detection method of such reflux.53,54 When 
twenty-four patients with untreated laryngeal or pharyngeal squamous cell 
carcinoma were evaluated by ambulant 24-hour pH monitoring; only 4 of 
these 24 head and neck cancer patients were found to have neither 
laryngopharyngeal or gastroesophageal reflux.55 A subsequent case-control 
study evaluating 22 patients with laryngeal SCC found an LPR rate of 63.9% 
compared to 20% in a control group (P=0.03).56 Within a similar large case-
control study, the multivariate analysis of Vaezi and colleagues also found 
GORD to be an independent risk factor for malignancy, although not to the 
same degree as smoking.57 
Gastroesophageal and gastropharyngeal reflux was monitored for the first 48 
hours of the immediate postoperative period following laryngectomy by 
Garrido et al.58 This pH-monitoring was conducted in 50 laryngectomy 
patients (40 total laryngectomies, 10 partial resections), detecting proximal 
reflux at the level of the pharyngeal closure in 40% of patients.  In another 
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post-treatment study, GPR was detected by ambulant 24-hour pH monitoring 
in 9 of 11 asymptomatic laryngectomised patients.59 Biacabe et al also 
conducted double-channel pH monitoring in 72 patients treated for 
pharyngolaryngeal carcinoma without symptoms of GORD; the incidence of 
silent reflux was approximately 37%.60 It was therefore concluded that 
patients with advanced pharyngolaryngeal malignancy should be 
appropriately monitored and treated for acid reflux during their entire course 
of therapy. 
The relationship between GORD and laryngeal carcinoma has, however, not 
yet been fully clarified and poses a significant epidemiological challenge. It 
has been recognised that a distinction between association and causality 
needs to be made whilst the matter is complicated by the relative rarity of 
carcinoma of the larynx when compared to the ubiquity of reflux.61 Existing 
case-control studies have been limited as controls need to be matched for 
lifestyle factors and there have been disparate study findings.62 Comparison 
of pH monitoring of 29 patients with carcinoma of the larynx with 2 groups of 
LPR patients, with and without benign laryngeal pathology did not detect a 
difference in the severity of reflux between the groups.63 Reflux was therefore 
not found to be an independent risk factor although LPR was detected in 
62% of the patients with malignancy. 
A recent case-control study by Francis and colleagues attempted to explore 
this association further, matching 14,449 cases of laryngeal carcinoma with 
controls, sourced from the Veterans Health Administration dataset.64 The 
resultant multivariate analysis did not reveal an association between GORD 
and laryngeal malignancy after adjustment for smoking and alcohol use. 
However further analysis did suggest a more specific link between GORD 
and glottic carcinoma whilst limitations relating to population bias and data 
consistency were acknowledged. This interpretation was mirrored by a large 
Swedish cohort study; no association was found after stratification for alcohol 
use was considered.65 Qadeer’s critical review concluded that the issue of 
causation remains unresolved; reflux may act as a co-carcinogen, 
possessing a synergistic role alongside smoking and alcohol to increase the 
risk of malignancy.66 
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Over and above an increased prevalence of GORD in comparison to the 
general population, the treatment of head and neck cancer patients has been 
postulated to further increase the risk of reflux disease. Laryngectomy 
surgery results in changes of innervation of the pharyngeal plexus and in 
oesophageal motility. A decrease in sphincter contraction at the level of the 
proximal oesophageal segment accompanied by a pressure decrease at the 
level of the upper oesophageal sphincter has been observed, increasing the 
risk of reflux.67,68  
Whilst it is suspected that reflux may play a role in the aetiology of squamous 
cell cancer of the larynx, it has also been considered as a contributing factor 
to complications in head and neck cancer patients after surgery or during 
radiotherapy. The relationship between reflux and complications relating to 
the creation of a tracheoesophageal fistula (TOF) for post-laryngectomy 
speech rehabilitation has generated significant research interest. Bock et al 
evaluated the deposition of pepsin in TOF sites by tissue and fluid analysis in 
17 laryngectomy patients finding pepsin in 12 subjects (58%). This appeared 
to be independent of the time from laryngectomy surgery and of reflux 
history.69 Several studies have also suggested a correlation between 
pathological reflux and phonatory prosthesis problems such as granulation, 
increased frequency of prosthesis change and unsatisfactory vocal results.70 
In the vast majority of studies reflux was detected in a high proportion of 
patients with phonatory prosthesis problems. Comprehensive anti-reflux 
treatment has also resulted in a significant improvement in prosthesis-related 
dysfunction.71 
Qadeer et al concluded that acid suppression therapy after treatment of 
laryngeal cancer (larynx-preserving surgery or chemo/radiotherapy) might 
have a protective effect in terms of recurrence.72 This was a retrospective 
case-control study in which a significant factor for decreased recurrence was 
acid suppressive therapy (hazard ratio 0.31 (95% confidence interval 0.13-
0.75). It was reflected that there were several study weaknesses including 
reviewed bias and the classification of GORD; a prospective study would be 
required to better define this possible effect. 
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Antacid Treatment 
A spectrum of treatment exists for GORD, the foundation being avoidance of 
aggravating factors. This prophylaxis comprises dietary and lifestyle 
modifications. A number of antacid medical treatments can supplement these 
adjustments. The first ‘phase’ of initial management includes the use of 
alginates and aluminium or magnesium containing antacids. These act to 
protect the oesophageal mucosa and are commonly used in response to 
symptoms. Histamine H2 receptor antagonists such as ranitidine and 
cimetidine traditionally represent the second phase of medical treatment, 
suppressing acid secretion by selective inhibition of the parietal cell by 
histamine. As H2 blockers do not inhibit other secretory pathways, total acid 
suppression is not achieved with these agents. Prokinetic drugs such as 
metocloperamide may also improve gastroesophageal sphincter function and 
gastric emptying.  
The most recent class of GORD medical treatment introduced in 1989 is the 
group of proton pump inhibitors (PPIs) or ‘hydrogen ion blockers’. These 
medications such as omeprazole and lansoprazole have been found to be 
the most potent suppressors of acid secretion, revolutionising the treatment 
of GORD.73 They act by irreversibly binding to and inhibiting the H+,K+-
ATPase enzyme of the gastric parietal cell.  This inhibits both basal and 
stimulated acid secretion, whether stimulated by food, acetylcholine or by 
gastrin.74 PPIs may be administered intravenously, orally and via a 
nasogastric feeding tube and have been proven to act within 24 hours to 
abolish acid secretion.75 This rapid efficacy and potential for once-daily 
dosage has been found to increase compliance.51 
Reflux Prophylaxis Following Total Laryngectomy 
Antacid regimes in the postoperative period following total laryngectomy are 
employed by some surgeons with the aim of reducing the incidence of 
postoperative pharyngocutaneous fistulae. There is, however, a limited 
evidence-base to support such prophylaxis. Using the aforementioned 
search strategy, two single case-control studies with retrospective controls 
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were identified (Level 3B evidence) whilst no Level 1 nor Level 2 evidence 
was found.17 
To date, medical literature describes the use of H2 antagonists (such as 
cimetidine and ranitidine) as antacids. Seikaly and Park reported a significant 
decrease in the incidence of PCF with a postoperative regimen of 
intravenous ranitidine and the prokinetic, metocloperamide hydrochloride;76 
twenty-three cases were treated prospectively with the antacid regime (PCF 
incidence 0%) in comparison to 17 retrospective controls that did not receive 
antacid treatment (PCF incidence 26%).  In this as yet small and specific 
research field this is a seminal study. It constituted a case-control study and 
did not benefit from randomisation. Although is stated that the two groups 
were evenly matched for other factors of PCF risk, such as preoperative 
radiotherapy and disease factors, possible bias could have been introduced 
due to the lack of prospective controls. The antacid regime employed was 
two-fold (metocloperamide and ranitidine); a conclusion regarding the 
individual impact of each medication cannot be made. A further negative 
aspect of this regime is the use of prolonged intravenous medication (7 
days). Of note, patients also received a week of intravenous antibiotics and 
an early feeding protocol was not used. The need for parenteral access for 
the first postoperative week could result in decreased patient mobility, and 
access site discomfort and sepsis. The associated cost of this regime of care 
is also a consideration. 
A reduction in PCF incidence following the addition of a prokinetic medication 
to a postoperative antacid regime was also described in 2000.77 
Metocloperamide hydrochloride was added to a previous protocol of 
ranitidine. Of the group of 55 patients, a total of 32.1% developed fistulae; 
39.4% in the ranitidine-only group and 21.7% in the ranitidine and 
metocloperamide group. As in Seikaly and Park’s study, intravenous 
medications were used for the first postoperative week and a protocol of 
early postoperative feeding was not used. There are, however, several 
identifiable weaknesses with this study. It is neither prospective nor 
randomised. Matching of the two groups is also not described. A statistically 
significant difference between the two groups could not be concluded. 
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Published literature evaluating the perioperative use of PPIs was not 
identified. This represents a significant gap both in the existing literature and 
in evidenced-based practice. Use of PPIs would be of particular interest 
given the demonstrated increased efficacy and rapidity of action of this class 
of medications. Given the significant morbidity associated with PCF 
development, accompanied by increased hospital stay and healthcare costs 
it is imperative that risk factors for the development of such a complication be 
identified and controlled as far as possible. In the context of a postoperative 
early feeding protocol, exploration of the use of enteral medication is of 
interest.  
To summarise, neither the use of a PPI nor the use of an enteral antacid 
preparation has been systematically examined; an exciting potential 
application of the PPI as reflux prophylaxis exists in the post-total 
laryngectomy setting. This generates an interesting research question. The 
ideal investigative study to determine whether a PPI would reduce the risk of 
PCF formation would be of prospective design using treatment and control 
groups. Randomisation into these 2 groups would reduce bias. ‘Blinding’ of 
the study would also increase its strength; a ‘double-blind’ format where 
neither patient nor healthcare professional is aware of the group of the 
patient is ideal. This is facilitated by use of a PPI placebo, identical in nature 
to the active drug so that neither clinician nor patient knows the true nature of 
the treatment received.  
 
 
 
 
 
 
 
 
Word Count: 3250 
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STRUCTURED ABSTRACT 
 
BACKGROUND: 
Pharyngocutaneous fistula is a common complication of total laryngectomy. 
We hypothesized that perioperative proton pump inhibitor (PPI) treatment 
could reduce the incidence of pharyngocutaneous fistulae. 
 
METHODS: 
This prospective placebo-controlled double-blind randomized controlled trial 
compared PPI treatment (14 days enteral omeprazole) with a placebo in 
patients undergoing primary total laryngectomy. The incidence of 
pharyngocutaneous fistula was recorded. 
 
RESULTS: 
Forty patients were randomized into PPI (N = 21) and placebo arms (N = 19). 
One of 21 patients receiving omeprazole developed a fistula in comparison to 
6 of 19 placebo group patients (p=0.04). No other statistically significant risk 
factors for pharyngocutaneous fistula were identified. The mean hospital stay 
of patients with and without a fistula was 32 and 7.5 days respectively. 
 
CONCLUSIONS: 
PPI prophylaxis was associated with a statistically significant reduction in 
pharyngocutaneous fistulae. As fistulae are associated with prolonged 
hospitalization and morbidity, PPIs are recommended for patients undergoing 
total laryngectomy. 
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INTRODUCTION 
Pharyngocutaneous fistula is a common complication following primary total 
laryngectomy and is a cause of significant patient morbidity. The reported 
incidence of pharyngocutaneous fistula ranges from 3% to 65% with a 
reported average of 17.4%;1 the incidence at our center has been previously 
evaluated and found to range between 15.4% and 20%.2   
 
Development of a pharyngocutaneous fistula delays oral feeding and is 
associated with a significantly increased duration of hospital stay. 
Bronchopneumonia, mediastinitis and severe sepsis, in addition to death as 
a result of erosion of the carotid artery have also been described.3–5 It is the 
principal short-term post-surgical complication to be avoided; all potential risk 
factors should be minimized. 
 
Over 65 studies relating to risk factors for pharyngocutaneous fistulae after 
total laryngectomy have been reported, whilst the published literature 
extends over a period of 40 years.1,6,7 Multiple risk factors have been 
considered thus far and include systemic disease, low preoperative 
hemoglobin and perioperative blood transfusion, low postoperative albumin, 
preoperative tracheostomy, concurrent neck dissection, type of pharyngeal 
closure, postoperative vomiting, positive surgical margins, and the use of 
perioperative antibiotics.8–12. Whilst there has been considerable disparity 
between studies, preoperative radiotherapy is thought to be the most 
significant factor identified to date.13,14 
 
A high incidence of gastroesophageal reflux disease (GERD) and 
gastropharyngeal reflux has been detected in patients with squamous cell 
carcinoma of the larynx in both pre- and post-laryngectomy populations.15–18 
There is, however, little published literature concerning reflux prophylaxis in 
the perioperative laryngectomy setting. Seikaly and Park compared a 
protocol of intravenous ranitidine and metoclopramide against retrospective 
controls; it was suggested that this prophylactic regime decreased the 
incidence of pharyngocutaneous fistulae.19 A non-statistically significant 
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reduction in fistulae following the addition of metoclopramide to a 
postoperative antacid regime of ranitidine has also been described.20 
 
The most recent class of medication to be introduced in the spectrum of 
GERD treatment is the group of proton pump inhibitors (PPIs). These 
medications such as omeprazole and lansoprazole have been found to be 
the most potent suppressors of acid secretion, revolutionizing the treatment 
of GERD.21 They act by irreversibly binding to and inhibiting the H+,K+-
ATPase enzyme of the gastric parietal cell. PPIs may be administered 
intravenously, orally or via a nasogastric feeding tube and have been proven 
to abolish acid secretion within 24 hours.22 This rapid efficacy and potential 
for once-daily dosage has been found to increase compliance.23 To our 
knowledge, neither the use of a PPI nor the use of an enteral antacid 
preparation has been systematically examined in the setting of total 
laryngectomy. This study was designed to evaluate the effect of this 
intervention on the incidence of pharyngocutaneous fistulae. 
 
MATERIALS AND METHODS 
Study population 
All patients with advanced carcinoma of the larynx scheduled for primary 
total laryngectomy surgery at our institution over a 25-month period (1st 
January 2011 to 31st January 2013) were eligible for inclusion.  
 
Study Design 
A prospective placebo-controlled double-blind randomized controlled trial 
was conducted. Randomization was computer generated and both 
participants and clinical staff remained blinded to intervention groupings for 
the entire duration of the trial. Prospective data collection included patient 
demographics and known relevant risk factors for pharyngocutaneous 
fistulae. 
 
All patients were managed according to an established ‘early feeding’ 
protocol.2 Perioperative antibiotic care was standardized; a single dose of 
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intravenous cefazolin was given intraoperatively followed by 24 hours of 
intravenous antibiotics (ampicillin 1g tds and metronidazole 500mg tds). 
The total laryngectomy surgery and the postoperative care remained 
unchanged other than the addition of the PPI or placebo.  The surgical 
method of closure of pharynx was also standardized. A 2-layer continuous 
closure with a vicryl 3/0 thread (Connell suture) in the shape of the least 
wound tension (either a horizontal or T-shaped closure) was performed by a 
consultant or a senior trainee under consultant supervision. A 
cricopharyngeal myotomy was routinely performed and a tracheoesophageal 
fistula created. Patients requiring a myocutanous flap for augmentation of the 
pharynx were excluded. 
 
A 20mg dose of omeprazole was administered once daily for 14 consecutive 
perioperative days, the first dose given the day before total laryngectomy 
surgery.  All doses were given enterally, either per os or via a feeding tube 
using a MUPS (Multiple Unit Pellet System) preparation. Local prescribing 
guidelines, of both the manufacturer of the medication and of local 
pharmacology authorities were followed.24  
 
Statistical analysis 
Proportions, mean and median values were calculated for all patient 
characteristics, as appropriate. The age distribution of the population was 
evaluated for normality with a Shapiro-Wilk test. Fisher’s exact test (2-sided) 
was used to evaluate the primary outcome of pharyngocutaneous fistula 
development. Logistic regression analysis was also applied to assess the 
predictors of fistula development; the ‘oddsrisk’ routine was employed to 
convert the odds ratio into a risk ratio since generalized linear models to 
estimate the risk ratio did not converge. A two-tailed significance level of 0.05 
was consistently used. Stata 11 software, StataCorp, College Station, Texas, 
USA was used to carry out all analyses.  
 
The University of Cape Town Human Research Ethics Committee approved 
this study and all patients gave written informed consent. 
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RESULTS 
A total of 40 patients (36 male and 4 female) underwent primary total 
laryngectomy at our institution during the 25-month study period and met our 
inclusion criteria. Mean patient age was 62.35 years (range 42-84 years); this 
was normally distributed.  
 
Fifty-five percent of patients had a background of systemic disease whilst 
12.5% had been previously treated for tuberculosis. A tracheostomy had 
been performed prior to total laryngectomy in 22 of the 40 patients (range 5-
224 days). Concurrent neck dissection was performed in 39 of 40 patients; 
unilateral and bilateral neck dissections were undertaken in 16 and 23 
patients respectively. A total of 62 neck dissections were performed (15 
selective, 45 modified radical and 2 radical). 
 
Pathological analysis revealed all tumors to be either T3 or T4 (7th edition 
American Joint Committee on Cancer (AJCC) staging system, 2009); 42.5% 
and 57.5% of patients had Stage 3 and 4 disease respectively. Metastatic 
neck disease was evident in 51.3% of the 39 patients who underwent neck 
dissection whilst nodal extracapsular spread was detected in 10 patients 
(25.6%). 
 
After randomization, 19 patients received a perioperative placebo whilst 21 
patients received PPI treatment. There were no statistically significant 
differences between patient and disease factors of the two groups (Table 1). 
None of the patients had previously been irradiated, had a prior diagnosis of 
GERD or was known to have received antacid treatment on a regular basis. 
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Table 1: Placebo and PPI treatment group data* 
 
Variable Placebo (n=19) PPI (n=21) 
Mean age 63.5 61.3 
Mean preop. haemoglobin (g/dl) 12.76 12.76 
Mean preop. albumin (g/l)‡ 37.15 38.90 
Systemic disease 11 of 19 (57.9%) 11 of 21 (52.4%) 
Prior tracheostomy (mean days) 32.4 38.0 
Prior tracheostomy 10 of 19 (52.6%) 12 of 21 (57.1%) 
Unilateral neck dissection 7 9 
Bilateral neck dissection 12 11 
Metastatic neck disease 7 of 19 (36.8%) 13 of 20 (65%) 
Nodal extracapsular spread  4 of 19 (21.1%) 6 of 20 (30%) 
Mean disease stage 3.53 3.62 
Abbreviations: Preop, preoperative. 
*No statistically significant difference between the two groups for any 
parameter (p>0.05); ‡ Results available for 24 of 40 patients. 
 
Seven patients (17.5%) developed a pharyngocutaneous fistula. A 
statistically significant difference was observed between the placebo and PPI 
treatment groups (Table 2). Spontaneous closure of the pharyngocutaneous 
fistula occurred in all cases  (mean 32 days, median 30 days) and no related 
mortality was recorded. No adverse effects of the 14-day course of 
omeprazole treatment were noted. 
 
 
Table 2: Incidence of pharyngocutaneous fistula 
 
Outcome Placebo PPI Total 
Fistula 6 (31.6%) 1 (4.8%)* 7  (17.5%) 
No fistula 13 20 33 
Total 19 21 40 
*Statistically significant (2-sided Fisher's exact test, p = 0.04) 
 
Postoperative hospital stay was defined as the number of postoperative days 
until a patient was deemed fit for discharge from a surgical perspective. 
Table 3 demonstrates the differences seen between both placebo and 
treatment groups and between those with and without a pharyngocutaneous 
fistula. 
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Table 3: Comparison of postoperative stay 
 
 Postoperative stay (days) 
Average Placebo PPI Fistula No fistula 
Mean (SD) 14.95 (14.60) 9.19 (8.72) 32.00 (17.67) 7.52 (1.23) 
Median (range) 8 (7-64) 7 (6-47) 34* (12-64) 7* (6-12) 
*Statistically significant (Wilcoxon rank-sum test, p = <0.001) 
 
The relative risk of other factors thought to influence pharyngocutaneous 
fistula risk is summarized in Table 4. A background of systemic disease was 
not found to be a statistically significant risk factor for pharyngocutaneous 
fistula development; the result is, however, suggestive of influence.  
 
Table 4: Patient and disease/management factors:  Evaluation of relative risk 
of pharyngocutaneous fistula  
Variable  N % Fistula 
development 
Risk ratio       
(95% CI) 
Systemic disease No 18 5.6  
4.9 (0.7 - 14.0) Yes 22 27.3 
Age  <60 18 16.7  
1.1 (0.2 - 3.2 ≥60 22 18.2 
Preoperative 
hemoglobin 
<11.5 12 16.7  
1.1 (0.2 - 3.4) ≥11.5 28 17.9 
Metastatic neck 
disease  
No 19 15.8  
1.3 (0.3 - 3.6) Yes 20 20.0 
Prior tracheostomy No 18 27.8  
0.3 (0.1 - 1.3) Yes 22 9.1 
Unilateral ND  No 24 20.8  
0.6 (0.1 - 2.2) Yes 16 12.5 
Bilateral ND No 17 11.8  
1.8 (0.4 - 5.2) Yes 23 21.7 
ECS No 29 23.8  
2.2 (0.5 - 5.1) Yes 10 30.0 
Margins <2mm or 
positive 
No 6 16.7  
1.1 (0.1 - 4.1) Yes 34 17.6 
     
Abbreviations: ECS, nodal extracapsular spread; ND, neck dissection. 
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DISCUSSION 
The relationship between reflux and carcinoma of the larynx is an intriguing 
one; the debate surrounding association and causality is ongoing.25–27 
It is clear, however, that patients with carcinoma of the larynx have a high 
prevalence of reflux. No patient in our study population had a prior diagnosis 
of GERD; the prevalence of GERD may be both underrepresented and 
undertreated in this group.  
 
The treatment of these head and neck cancer patients has been postulated 
to further increase the risk of reflux. Laryngectomy results in changes in 
pharyngeal plexus innervation and in esophageal motility; a pressure 
decrease at the level of the upper esophageal sphincter has been 
observed.30,31 Reflux is also recognized as a key factor in phonatory 
prosthesis problems in the context of post-laryngectomy speech 
rehabilitation.28,29  
 
Evaluation of reflux by pH-monitoring for the first 48 hours of the immediate 
postoperative period following laryngectomy has also detected proximal 
reflux at the level of the pharyngeal closure in 40% of patients.32 The effect of 
this refluxate upon the upper aerodigestive tract mucosal lining has been 
examined; mucosal erosion, ulceration and submucosal hemorrhages were 
recorded as a result of exposure to pepsin or to pepsin and hydrochloric acid 
in animal models.33,34 Experimental studies have also shown that intermittent 
reflux of only 3 episodes per week is sufficient to produce laryngeal damage 
when mucosal injury is present.35 This generates the hypothesis that reflux 
may contribute to poor wound healing and development of a 
pharyngocutaneous fistula. 
 
The randomization of patients within this study resulted in matching of the 
placebo and treatment groups whilst the prospective double-blind design 
reduced the potential for introduction of bias. The overall incidence of 
pharyngocutaneous fistula was 17.5% and is comparable with reporting from 
other centers.10 The statistically significant difference between the proportion 
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of fistulae in the placebo and treatment groups supports the hypothesis that 
PPI reflux prophylaxis reduces the incidence of pharyngocutaneous fistulae. 
 
Omeprazole is both widely available and inexpensive. The current pharmacy 
cost in our center of the treatment regime employed is 10.31 South African 
Rand/$1.16 per patient. The medication is also easy to administer; lengthy 
parental administration is avoided and duplication in both first and third world 
settings is facilitated.   
It is evident that our population presents with advanced disease. A prior 
tracheostomy was necessary in a large proportion of our patients. The wide-
ranging interval between tracheostomy and total laryngectomy reflects 
several factors; delays in presentation to medical services and deviation from 
advised management plans often occur, coupled with pressure on surgical 
services.  
 
 
CONCLUSIONS 
Development of a pharyngocutaneous fistula is a common yet potentially 
devastating complication following total laryngectomy. It significantly 
increases hospital stay and cost, postpones oral intake, delays speech 
rehabilitation and can delay further treatment such as radiotherapy.  
 
The use of perioperative enteral omeprazole is associated with a significant 
reduction in the incidence of pharyngocutaneous fistula in our setting. This 
strengthens the argument that postoperative reflux may contribute to 
pharyngocutaneous fistula formation. PPIs are recommended for patients 
undergoing total laryngectomy. 
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APPENDIX I:  DATA COLLECTION 
 
PATIENT FACTORS 
• Hospital number 
• Age  
• Sex 
• Smoking and  alcohol intake history 
• Diabetic / Non-diabetic 
• Other major medical co-morbidity (COPD, CCF, HTN, liver disease) 
• Nutritional status  -   albumin levels (pre/post-op) 
• HIV status (and CD4 count) 
• History of GORD prior to surgery 
• Diabetic / Non-diabetic 
• Haemoglobin levels (pre / post – op) 
• ?Anaesthetic risk category 
DISEASE-RELATED 
• Previous radiotherapy & time interval between RT and surgery 
• Previous tracheostomy  
 
PROCEDURE-RELATED 
• Suture material used 
• Method of pharyngeal closure 
• Myotomy performed 
• Clearance of margins 
• Nodal status – clinical stage and histologic grading 
• Simultaneous neck dissection 
POST-OPERATIVE FACTORS 
• Local wound complications – haematoma, infection, breakdown 
• Day of post-op feeding 
• Drainage method and duration 
• Post-op haemoglobin / blood transfusion required 
• Post-operative vomiting 
IN CASES OF PHARYGOCUTANOUS FISULA 
• Day post-op developed 
• Site 
• Spontaneous closure? 
• Surgical closure? – method 
• Day post-op closed 
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PHARYNGOCUTANEOUS FISTULA POST-TOTAL LARYNGECTOMY STUDY
Data sheet to be completed for all patients 
Date of surgery:
Name:
Hospital number: 
Age at surgery:
Sex: M / F
Smoking history: Current smoker / Ex – smoker / Lifetime non-smoker
Cigs / day:
Alcohol use: Teetotal / Ex-drinker / Drinker
(No. of units / week)
Diabetic: Y / N
Other major medical co-morbidity (COPD, CCF, HTN, liver disease)? Please give details:
Anaesthetic risk category: ASA  I / II / III / IV
Haemoglobin: pre-op post-op 
Albumin level: pre-op post-op
HIV status: +    /     -       / refuses testing
CD4 count: 
PMH of GORD Y    /    N    /   List current antacids:
Previous radiotherapy: Y   /   N
- time interval between RT and surgery 
Previous tracheostomy: Y   /   N
-         time interval between tracheostomy and surgery 
Pre-op. staging: T____    N____
TOTAL LARYNGECTOMY SURGERY
Suture material used:
Method of pharyngeal closure: 
[Longitudinal / T – shape), Number of layers]
Myotomy performed: Y   /   N
Clearance of margins: Y   /   N
Nodal status – clinical stage and histologic grading:   T____    N _____
Simultaneous neck dissection: Y   /   N
Unilateral / bilateral / selective / comprehensive
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POST-OPERATIVE PERIOD
Local wound complications: 
(haematoma, infection, breakdown)
Early feeding protocol used: Y   /   N
Day post-op. started soft diet:
Day post-op. drain removed: 
Blood transfusion required: Y   /   N
Post-operative vomiting: Y   /   N
Date declared fit for discharge from surgical perspective:  
(excluding social and voice restoration issues) 
IN CASES OF PHARYNGOCUTANEOUS FISTULA:
Day post-op developed:
Diagnostic criteria: Fever  /  Cellulitis  / Clinical appearance of fistula  / Contrast swallow
Site of PCF: Left Right
(Give details) 
Day post-op fistula closed:     Spontaneous closure?
Surgical closure? (details)
Any queries, please contact Dr. Kate Stephenson, speed dial 76617
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APPENDIX II:  EARLY FEEDING PROTOCOL 
 
 
Day Feeding 
 
 0 (day of operation) NBM + IV fluids 
1 NBM + tube feeds 
2 Clear fluids PO + 1500ml tube feeds 
3 Free fluids PO + 1500ml tube feeds 
4 Soft diet PO + 1500ml tube feeds  
5 Full ward diet + 500ml feeds PO/NG 
6 and onwards As above 
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APPENDIX III:  CONSENT FORM 
 
 
CONSENT TO ACT AS A SUBJECT IN A CLINICAL STUDY 
 
TITLE: DO PROTON PUMP INHIBITORS REDUCE THE INCIDENCE OF 
PHARYNGOCUTANEOUS FISTULAE FOLLOWING TOTAL LARYNGECTOMY? 
 
INVESTIGATORS: Dr Kate Stephenson and Professor Johan Fagan. 
 
ADDRESS FOR ALL INVESTIGATORS: Division of Otolaryngology, H53, Old Main 
Building, Groote Schuur Hospital, Observatory, Cape Town, 7925 
 
 
 
DESCRIPTION:. You are being asked to participate in this study, which may 
necessitate the following:  
 
Receiving an anti-acid medicine either by mouth or through a feeding tube to the stomach in 
the time after your laryngectomy (removal of the voice box) for cancer. Half of the patients in 
this study will receive this extra medicine and half will not; this will be decided randomly (i.e. 
by a method like flipping a coin). 
 
RISKS AND BENEFITS: There are no known risks or benefits to you. 
 
COSTS AND PAYMENTS: There will be no additional costs to you or your family.  
 
CONFIDENTIALITY: The information obtained from this study will be published in the future 
such that your identity will remain anonymous.  Medical records related to this study are 
confidential, but may be examined by researchers from this institution.   
 
RIGHT TO WITHDRAW: You have the right to refuse to participate in this study at any time, 
and your decision will not adversely affect your care at this institution. 
 
VOLUNTARY CONSENT: I understand what is stated above and agree to participate in this 
clinical trial. 
 
     
 
 
 
 
 
Patient Signature………………………………….. 
 
    
I certify that I have explained to the above individual the nature and purpose, the potential 
benefits, and possible risks associated with participating in this research study, have 
answered any questions that have been raised and have witnessed the above signature. 
 
 
 
Witness / Researcher: Name……………………………         
 
Signature……………...………………… 
	  Patient	  Name…………………………………………	  	  Hosp	  No……………………..	  D.O.B:…./…../..….	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APPENDIX IV:  
HUMAN RESEARCH ETHICS COMMITTEE APPROVAL & UPDATES 
 
 
 
 
 
PI 
UNIVE RSITY OF CAPE TOWN 
24 June 2010 
HREC REF: 186/2010 
Dr K Stephenson 
Otolaryngology 
H53, Old Main Building 
Dear Dr Stephenson 
Health Sciences Faculty 
Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021] 406 6626 • Facsimile [021] 406 6411 
e-mail: shuretta.thomas@uct.ac.za 
PROJECT TITLE: DO PROTON PUMP INHIBITORS REDUCE THE INCIDENCE OF 
PHARYNGOCUTANEOUS FISTULAE FOLLOWING TOTAL LARYNGECTOMY? 
Thank you for responding to the issues raised by the Faculty of Health Sciences Human Research Ethics 
Committee. 
It is a pleasure to inform you that the Ethics Committee has formally approved the above-mentioned study. 
Please add the HREC contact details on the Informed Consent Document. 
Approval is granted for one year till the 30th June 2011. 
Please submit an annual progress report if the research continues beyond the expiry date. Please submit a brief 
summary of findings if you complete the study within the approval period so that we can close our file. 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal 
investigator. 
Please quote the-REC. REF in all your correspondence. 
Yours sincerely 
~RfL~ 
PROFESSOR M BLOCKMAN 
CHAIRPERSON, HSF HUMAN ETHICS 
Federal Wide Assurance Number: FWA00001637. 
SThomas 
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UNIVERSITY Of CAPE TOWN 
FACUL TV OF HEALTH SCIENCES 
Human Research Ethics Committee 
Annual Progress Report 
Date 10TH May 2011 
HREC REF Number 186/2010 
Protocol number (if DO PROTON PUMP INHIBITORS REDUCE THE INCIDENCE OF 
applicable) & Protocol PHARYNGOCUTANEOUS FISTULAE FOLLOWING TOTAL 
title LARYNGECTOMY? 
Principal Investigator Dr. Kate Stephenson 
Department / Office Department of Otorhinolaryngology, H-53, Old Main Building, Groote 
Internal Mai l Address Schuur Hospital 
List of documentation 
N/A 
, t 
HREC office use only (FWA00001637; IRBOOOO1938) 
Approved V This serves as notification of annual approval, including all documentation described 
above. 
Not approved See attached comments. 
Type of review Expedited V 
I 
Full committee 
Expiry date IS J ~f\)e 2012-
Signature 
~Jie~ I Date 100 1( Chairperson of the HREC 
V U 
7 October 2010 Page 5 of 5 FHS016 
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UNIVER!>1f '( OF CA!'l: H.J'NN 
. .. FACULTY OF HEALTH SCIENCES 
Human Research Ethics Committee 
Annual Progress Report 
Date 21th Sept 2012 
HREC REF Number 186/2010 
Protocol number (if DO PROTON PUMP INHIBITORS REDUCE THE INCIDENCE OF 
applicable) & Protocol PHAR YNGOCUTANEOUS FISTULAE FOLLOWING TOT AL 
title LARYNGECTOMY? 
Principal Investigator Dr. Kate Stephenson 
Department I Office Department of Otorhinolaryngology, H-53, Old Main Building, Groote 
Internal Mall Address Schuur Hospital 
List of documentation 
N/A 
- - . --_ .... • 
RESEARCH ETHICS COMMITrEE I 
I 
2012 -09- 2 8 • I ! 
HEALTH SCIENCES FACUlTY i 
UNIVERSITY OF CAPE TOWN i 
____ ._ .. ___ .. _ I 
H~C office use only (FWA00001637; IRBOOOO1938) 
...I"f Approved This serves as notification of annual approval. including all documentation described 
above. 
o Not approved See attached comments. 
/ 
Type of review • Okxpedited o Full committee 
Expiry date /5 S; eP TE fVI 8E"R. 201:3 
Signature Date 
Chairperson of the HREC pp '\03Jtl.z~:,') Os \ to i2.0\2.. 
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APPENDIX V:  
DEPARTMENTAL RESEARCH ETHICS COMMITTEE APPROVAL 
UNIVERSITY OF CAPE TOWN 
23rd April 2010 
Dr K Stephenson 
Department of Surgery 
Division of Otolaryngology 
Groote Schuur Hospital 
University of Cape Town 
Dear Dr Stephenson 
RE: PROJECT 2010/025 
Department of Surgery 
Departmental Research Committee 
Professor Anwar Sui em an Mall 
J-45 Room Old Main Building, Groote Schuur Hospital, 
Observatory 7925, South Africa 
Tel (021) 4066168/ 6232/6227 Fax (021 ) 448 6461 
Email: Anwar.Mall®uct.ac.za 
PROJECT TITLE: Do proton pump inhibitors reduce the incidence of pharyngocutaneou$ 
fistulae following total laryngectomy 
The above proposal was reviewed by the Department of Surgery Research Committee and I am 
pleased to inform you that the committee approved the study. 
Please use the above project number in all future correspondence. 
Yours sincerely 
M~ 
PROFESSOR ANWAR SMALL 
CHAIRMAN: RESEARCH COMMITTEE 
"OUR MISSION is to be an outstanding teaching and research university, 
educating for life and addressing the challenges facing our society. " 
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APPENDIX VII:  AUTHOR GUIDELINES: HEAD & NECK 
 
Edited By: Ehab Y. Hanna, MD 
Impact Factor: 2.403 
ISI Journal Citation Reports © Ranking: 2011: 5/41 (Otorhinolaryngology); 
46/199 (Surgery) 
Online ISSN: 1097-0347 
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-
0347/homepage/ForAuthors.html [accessed 8 March 2013] 
 
NIH Public Access Mandate  For those interested in the Wiley-Blackwell 
policy on the NIH Public Access Mandate, please visit our policy statement 
For additional tools visit Author Resources - an enhanced suite of online 
tools for Wiley InterScience journal authors, featuring Article Tracking, E-mail 
Publication Alerts and Customized Research Tools. 
• Copyright Transfer Agreement 
• Permission Request Form 
• Online Manuscript Submission 
• Wiley's Journal Styles and EndNote 
• Authorship Disclosure Form 
• The National Institutes of Health Public Access Initiative 
 
Manuscript Submission 
Manuscripts should be submitted online at 
http://mc.manuscriptcentral.com/hed . 
Submit all new manuscripts online. Launch your web browser and go to 
http://mc.manuscriptcentral.com/hed . Check for an existing account. If you 
are submitting for the first time, and you do not have an existing account, 
create a new account. Follow all instructions. 
Submit manuscript and all figures as one file if possible. You do not need to 
mail any paper copies of your manuscript. 
Along with the manuscript file, please upload a Cover Letter (designated "not 
for review") which includes the contact information of the corresponding 
author, a statement of financial or other relationships which may lead to a 
conflict of interest, and which references any published reports that may 
duplicate material in the submitted manuscript. Signed releases from 
patient(s) or guardian(s) for use of any recognizable patient photographs 
may be faxed separately, or scanned and uploaded as part of the online 
submission. 
At the end of a successful submission, a confirmation screen with manuscript 
number will appear and you will receive an e-mail confirming that the 
manuscript has been received by the journal. If this does not happen, please 
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check your submission and/or contact tech support at edsupport@wiley.com  
Copyright. No article can be published unless accompanied by a signed 
copyright transfer agreement, which serves as a transfer of copyright from 
author to publisher. A copyright transfer agreement may be obtained from the 
editor or the publisher. A copy of the agreement appears in most issues of 
the journal. Only original papers will be accepted and copyright in published 
papers will be vested in the publisher. It is the author's responsibility to obtain 
written permission to reproduce material that has appeared in another 
publication. 
 
Style 
Sources. Webster's Third New International Dictionary (Springfield, MA: 
Merriam-Webster, Inc) should be used for spelling and hyphenation of 
nonmedical terms, and Dorland's Illustrated Medical Dictionary , 27th ed 
(Philadelphia: WB Saunders) for medical terms. The author is directed to the 
American Medical Association Manual of Style , 8th ed, for general style. 
Measure (length, height, weight, and volume) should be reported in units or 
their decimal multiples. Temperature should be given in degrees Celsius, and 
blood pressure should be given in millimeters of mercury. All hematologic 
and clinical chemistry measurements should b  reported in the metric system 
in SI (international system) units. 
Numbers. Use numerals for all units of measure and time. Spell out the 
numbers one through nine only for general usage (eg, "We considered only 
two possibilities.") Spell out numbers beginning a sentence. 
Abbreviations. Use only standard abbreviations. Avoid abbreviations in the 
title. The full term for which an abbreviation stands should precede its first 
mention in the text. Only standard abbreviations as listed in the AMA Manual 
of Style should be used without definition. 
 
Manuscript Preparation 
Title Page. The title page should include (1) a concise and informative title of 
the article using terms that can be readily indexed; (2) the authors' full names 
(first name, middle initial, surname) with highest earned degrees; (3) 
affiliations for each author (department, section, institution, city and state or 
country where the work was done); (4) acknowledgment of grant support and 
of individuals who were of direct help in the preparation of the study; (5) 
identification of meetings at which the manuscript was presented, if 
appropriate; (6) the name, address, telephone number, and email address of 
the author to whom correspondence and/or reprint requests are to be sent; 
(7) a brief running title; and (8) five key words for indexing. 
Authorship. All persons designated as authors should have participated 
sufficiently in the work to take public responsibility for the content of the 
manuscript. Authorship credit should be based on substantial contributions to 
(1) conception and design or analysis and interpretation of data, (2) drafting 
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of the manuscript or revising it for important intellectual content and, (3) final 
approval of the version to be published. The Editor may require the authors 
to justify assignment of authorship. In the case of collective authorship, the 
key persons responsible for the article should be identified and others 
contributing to the work should be recognized with proper acknowledgment. 
Abstract. Page 2 should include a structured abstract of no more than 150 
words, divided into the following subheadings: Background, Methods, 
Results, and Conclusions. 
Text. Manuscripts should be organized in the following format: Introduction, 
Materials and Methods, Results, and Discussion. Other descriptive headings 
and subheadings may be used if appropriate. The content of the study 
should be presented as clearly and concisely as possible. In the methods 
section, the selection process for observational and experimental subjects 
should be defined clearly. Identify methods, apparatus (manufacturer's name 
and address), and procedures in sufficient detail to allow other workers to 
reproduce the results. References should be given for discussions of 
previous studies and for all nonstandard methods used. When reporting 
experiments on human subjects, indicate whether the procedures followed 
were in accordance with the ethical standards of the committee on human 
experimentation of the institution or in accord with the Helsinki Declaration of 
1975 as revised in 1983. For experiments on animals, indicate whether the 
institution's or the National Research Council's guide for the care and use of 
laboratory animals was followed. For drugs and chemicals, the generic name 
should be used at first mention and preferably thereafter. Trade names may 
appear in parentheses and should be capitalized. Do not use patients' 
names, initials, or hospital numbers, especially in figures or tables. Describe 
statistical methods with enough detail to enable a knowledgeable reader with 
access to the original data to verify the reported results. Reference the 
statistical methodology employed. Specify any general-use computer 
programs used. 
Present your results in logical sequence in text, tables, and figures. Avoid 
duplication of data in the text and tables, figures, or both. Emphasize or 
summarize only important observations. In a discussion, emphasize new and 
important aspects of the study and the conclusions that follow from them. 
Avoid repetition and present recommendations. If case reports are necessary 
to illustrate a point, they should contain only the pertinent information. 
All tables and figures should be numbered consecutively at first mention in 
the text. All data cited in the text should be checked carefully against data in 
the tables to be sure they correspond. All names cited in the text should be 
checked carefully against the references to ensure the spelling is correct. 
References. 
All references should be cited in consecutive numerical order at first mention 
in the text. Type references double-spaced and list them consecutively not 
alphabetically. Identify references in the text, tables, and legends by Arabic 
numerals typed as superscripts. References cited only in a table or in a figure 
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legend should be numbered in accordance with a sequence established by 
the first mention in the text of the particular table or figure. Head & Neck 
follows the Uniform Requirements for reference style: 
Journal article (list all authors when six or less; when seven or more, list 
only first three and et al.) 
King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, 
lateral reticular, and inferior olivary projections to two paravermal cortical 
zones of the cat cerebellum. J Comp Neurol 1998;390:537-551. 
Book 
Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p. 
Book chapter 
Gilmor ML, Rouse ST, Heilman CJ, Nash NR, Levey AI. Receptor fusion 
proteins and analysis. In: Ariano MA, editor. Receptor localization. New York: 
Wiley-Liss; 1998. p 75-90. 
Journal names should be abbreviated in Index Medicus style. Unprivileged 
observations and personal communications should not be used as 
references, although written nonverbal communications may be noted as 
such in the text. References cited as "in press" must have been accepted 
and not merely in preparation or submitted. Unpublished observations and 
personal communications must not appear in the references, but may be 
cited in parentheses in the text. The author is responsible for the accuracy 
and completeness of references. 
Tables. Do not submit tables as photographs. Wide tables are difficult to 
typeset and should be avoided by restructuring or breaking them into smaller 
tables. Each table must have a title, and every column in the table including 
the left-hand column should have a concise heading. Define all abbreviations 
in a footnote to the table and indicate the units of measurement for all values. 
Use commas for all numbers exceeding 999 and use zeroes before decimals 
for numbers less than one. Organize the tables so that like data are read 
vertically, not horizontally. 
Do not use internal horizontal or vertical lines to separate sections. Explain 
all empty spaces or dashes; indicate footnotes to the table using symbols in 
the order shown: * (asterisk), † (dagger), ‡ (double dagger), § (section mark),  
(parallels), ¶ (paragraph mark), # (number sign). Care should be taken to 
limit the number of footnotes to seven or less. If data from any other source, 
published, or unpublished, are used, the author must obtain written 
permission for their use and cite the source in the footnotes. 
Figures. Figures should be large enough to remain legible when reduced for 
publication. Be sure all spelling is correct, letters and lines are unbroken and 
type is even, and the abbreviations used are consistent with those in the text. 
For photographs of identifiable persons, written permission from the subject 
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must be supplied or the subject's eyes will be masked. 
All color figures will be reproduced in full color in the online edition of the 
journal at no cost to authors. Authors are requested to pay the cost of 
reproducing color figures in print. Authors are encouraged to submit color 
illustrations that highlight the text and convey essential scientific information. 
For best reproduction, bright, clear colors should be used. Dark colors 
against a dark background do not reproduce well; please place your color 
images against a white background wherever possible. The cost of printing 
figures in color is as follows: $950 for the first page; $450 for pages 2 through 
4; $950 page 5 and after. 
Figure legends. Legends should be typed double-spaced and labeled with 
Arabic numerals corresponding to the illustrations. When symbols, numbers, 
or letters are used to identify areas of the figure, each should be clearly 
explained in the legend. For photomicrographs, the method of staining and 
original magnification must be given. If the figure has been previously 
published, a credit line should be included and permission to reprint from the 
publisher supplied. 
 
Review Process 
All manuscripts are reviewed by the Editor and at least two expert reviewers 
in the field. The decision of the Editor is final and may require more than one 
revision of the manuscript. All material accepted for publication is subject to 
copy editing. The corresponding author will receive page proofs of articles 
before publication and should answer all queries and carefully check all 
editorial changes at this stage. Authors are responsible for the scientific 
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APPENDIX VIII:  POST-STUDY EVALUATION 
Sample Size 
From statistical power calculations it was initially anticipated that 50 patients 
would be recruited into each arm of the study, with an estimated trial duration 
of 2 years. In the 25-month study period, a total of 40 patients were eligible 
for inclusion within the analysis. Several factors affecting patient numbers 
can be identified.  Firstly, the trial start date was later then hoped due to 
delay in availability of medicines and subsequent necessary detailed 
planning with the hospital pharmacy.  Patient numbers were also reduced by 
adherence to strict inclusion criteria; cases requiring extended surgery such 
as loco-regional flaps were excluded in addition to those who were not 
managed according to an early feeding protocol, as described. Cases in 
which the medicine was not administered as intended were also excluded. 
The termination point of the study was dictated by the expiry date of the 
available medications used specifically for purposes of the trial.  
Amendments to the protocol were not required and there were no deviations 
from the protocol in those cases considered eligible for inclusion within the 
study. 
Future research 
Several areas of further research related to this work can be identified. 
Additional experimental studies may serve to better characterise and quantify 
the damaging effect of refluxate upon the pharyngeal mucosa. A better 
understanding of the degree and nature of reflux in both pre- and post-
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laryngectomy populations would also support possible interventions.  This 
could be approached in several ways; reported symptoms, pH monitoring, 
endoscopy and combined pH-impedance monitoring are possible methods of 
evaluation. 
Similar trials, ideally also of double-blind, placebo-controlled design could 
also be compared to this work and facilitate a meta-analysis. Larger patient 
numbers might be achieved with a multi-centre set-up. Variations in the 
dosage and mode of administration of the proton pump inhibitor (intravenous 
versus enteral) would also be avenues of exploration, in addition to use of 
other medicines within the same class or combinations of antacids. 
Comparative continuous (24 hours or greater) pH monitoring in the 
perioperative period would be an ideal tool for evaluation of the reflux pattern 
and impact of the proton pump inhibitor. 
Examination of the use of omeprazole in the perioperative care of ‘salvage 
laryngectomies’, after radiotherapy or chemoradiotherapy would also be of 
interest, particularly as the risk of pharyngocutanous fistula is recognised to 
be higher in these circumstances.   
This work suggests that there is significant potential for reduction of 
pharyngocutanous fistulae and improved patient outcomes. High quality 
research is required to definitively answer the question of the impact of reflux 
on risk of developing pharyngocutaneous fistulae after total laryngectomy. 
Numerous additional patient, disease and management-related potential risk 
factors may confound the issue, necessitating extensive data collection and 
evaluation.  
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APPENDIX IX:  LIST OF CORRECTIONS 
 
 
1. Spelling: correction of counseled to counselled (p.16) 
 
2. Addition of Appendix VIII: Post-study evaluation 
 	  
 
  
